OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	195
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	191
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	142
Steroid tapering after GVHD Rx: not too fast, not too slow	141
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	136
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	132
Addressing and overcoming disparities in GVHD	127
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	120
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	113
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	113
On a collision course: SARS-CoV-2 variants and CAR T cells	112
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	112
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	105
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	101
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	99
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	98
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	93
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	92
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	91
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	90
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	88
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	86
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	86
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	85
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	84

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	84
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	84
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	83
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	83
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	79
Bite-size introduction to canine hematologic malignancies	76
Best but not perfect: indirect measure of low iron stores	76
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	76
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	75
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	73
Transfusion therapy for sickle cell disease: what’s new?	72
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	69
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	66
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	66
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	64
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	63
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	63
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	63
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	63
Complement C5 inhibition in early onset HELLP syndrome	62
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	61
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	61
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	60
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	60
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	60
CD58 loss in tumor cells confers functional impairment of CAR T cells	60
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	59
Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse	59
Applying CRISPR-Cas9 screens to dissect hematological malignancies	58
Cortisol in Sickle Cell Disease: A Systematic Review and Meta-Analysis	58
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	58
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	57
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	57
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients	57
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	57